We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

112 hedge funds and large institutions have $176M invested in Rigel Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,704% more call options, than puts

Call options by funds: $1.39M | Put options by funds: $77K

60% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 10

53% more capital invested

Capital invested by funds: $115M → $176M (+$61.3M)

36% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 28

6% more funds holding

Funds holding: 106 → 112 (+6)

0.85% more ownership

Funds ownership: 6.09% → 6.94% (+0.85%)

Holders
112
Holders Change
+6
Holders Change %
+5.66%
% of All Funds
1.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
38
Reduced
28
Closed
10
Calls
$1.39M
Puts
$77K
Net Calls
+$1.31M
Net Calls Change
+$515K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$22.4M
2
BlackRock
BlackRock
New York
+$802K
3
GCP
GSA Capital Partners
United Kingdom
+$466K
4
Squarepoint
Squarepoint
New York
+$331K
5
ZIM
Zacks Investment Management
Illinois
+$309K

Top Sellers

1
SCM
Soleus Capital Management
Connecticut
-$5.48M
2
Millennium Management
Millennium Management
New York
-$2.39M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$796K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$700K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$381K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$742K -$75.1K -7,348 -13%
PWA
27
Providence Wealth Advisors
Illinois
$619K -$21.3K -2,080 -76%
Los Angeles Capital Management
28
Los Angeles Capital Management
California
$586K – – –
Squarepoint
29
Squarepoint
New York
$469K +$331K +32,379 New
AllianceBernstein
30
AllianceBernstein
Tennessee
$456K – – –
ZIM
31
Zacks Investment Management
Illinois
$438K +$309K +30,235 New
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$435K +$53K +5,183 +21%
Barclays
33
Barclays
United Kingdom
$357K +$209K +20,485 +492%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$333K +$1.28K +125 +0.5%
Fidelity Investments
35
Fidelity Investments
Massachusetts
$297K +$1.58K +155 +0.8%
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$295K +$26.5K +2,591 +15%
NSEDCP
37
NJ State Employees Deferred Compensation Plan
New Jersey
$290K – – –
EFMC
38
Empire Financial Management Company
New York
$280K +$197K +19,300 New
SO
39
STRS Ohio
Ohio
$256K – – –
Bank of America
40
Bank of America
North Carolina
$247K +$73.6K +7,200 +73%
UBS Group
41
UBS Group
Switzerland
$219K +$74.8K +7,319 +94%
Russell Investments Group
42
Russell Investments Group
United Kingdom
$211K -$48.8K -4,772 -25%
Principal Financial Group
43
Principal Financial Group
Iowa
$208K +$22.2K +2,170 +18%
JP Morgan Chase
44
JP Morgan Chase
New York
$186K -$87.8K -8,583 -40%
CWM
45
Connecticut Wealth Management
Connecticut
$167K – – –
SOW
46
State of Wyoming
Wyoming
$163K +$26.7K +2,613 +30%
T. Rowe Price Associates
47
T. Rowe Price Associates
Maryland
$151K +$3.76K +368 +4%
Two Sigma Investments
48
Two Sigma Investments
New York
$150K -$169K -16,567 -62%
WMSA
49
Weiss Multi-Strategy Advisers
New York
$147K -$18.3K -1,787 -15%
MIM
50
MetLife Investment Management
New Jersey
$134K – – –
1
2
3 4 5

RIGL Hedge Fund Activity: Q4 2023 in Review

112 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2023, worth a combined $176M — up 53% from $115M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new RIGL positions and 10 closed out — a net gain of 6 holders — while 38 added to existing stakes and 28 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $22.4M. The largest seller was Soleus Capital Management, cutting an estimated $5.48M.

  • 112 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2023, up from 106 in Q3 2023.
  • Funds reported $176M of Rigel Pharmaceuticals stock for Q4 2023, up 53% quarter-over-quarter.
  • 16 funds opened new Rigel Pharmaceuticals positions in Q4 2023 and 10 closed out, a net change of +6 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $22.4M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2023 was Soleus Capital Management, an estimated $5.48M sold.

Based on aggregated 13F filings for Q4 2023.